{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:50:43Z","timestamp":1764784243429,"version":"3.37.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1124\/dmd.119.086785","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T01:35:17Z","timestamp":1559612117000},"page":"899-906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-1184","authenticated-orcid":false,"given":"Jacqueline","family":"Bezen\u00e7on","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-8844","authenticated-orcid":false,"given":"James J.","family":"Beaudoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-5033","authenticated-orcid":false,"given":"Dong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharin E.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-4929","authenticated-orcid":false,"given":"Kim L.R.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.119.086785_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/dmd.118.083907","article-title":"Altered hepatobiliary disposition of tolvaptan and selected tolvaptan metabolites in a rodent model of polycystic kidney disease [published correction appears in Drug Metab Dispos (2019) 47:328]","volume":"47","author":"Beaudoin","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086785_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/1091581818760746","article-title":"Bile acids as potential biomarkers to assess liver impairment in polycystic kidney disease","volume":"37","author":"Brock","year":"2018","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.119.086785_bib3","series-title":"Models for Assessing Drug Absorption and Metabolism","first-page":"161","article-title":"Isolated perfused liver","author":"Brouwer","year":"1996"},{"key":"10.1124\/dmd.119.086785_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1023\/B:PHAM.0000026420.79421.8f","article-title":"The complexities of hepatic drug transport: current knowledge and emerging concepts","volume":"21","author":"Chandra","year":"2004","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.119.086785_bib5","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.105.003665","article-title":"Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver","volume":"33","author":"Chandra","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086785_bib6","doi-asserted-by":"crossref","first-page":"G1252","DOI":"10.1152\/ajpgi.00362.2004","article-title":"Short-term regulation of multidrug resistance-associated protein 3 in rat and human hepatocytes","volume":"288","author":"Chandra","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/dmd.119.086785_bib7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1681\/ASN.V1191767","article-title":"Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma","volume":"11","author":"Chauveau","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.119.086785_bib8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/dmd.119.086785_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-9-69","article-title":"Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management","volume":"9","author":"Cnossen","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/dmd.119.086785_bib10","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile acid transporters","volume":"50","author":"Dawson","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1124\/dmd.119.086785_bib11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1172\/JCI114189","article-title":"Hepatobiliary transport of glutathione and glutathione conjugate in rats with hereditary hyperbilirubinemia","volume":"84","author":"Elferink","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.119.086785_bib12","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.1840080626","article-title":"Polycystic liver disease: quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts","volume":"8","author":"Everson","year":"1988","journal-title":"Hepatology"},{"key":"10.1124\/dmd.119.086785_bib13","first-page":"69","article-title":"Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment","volume":"3","author":"Halvorson","year":"2010","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1124\/dmd.119.086785_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1124\/dmd.119.086785_bib15","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1542\/peds.2013-3646","article-title":"Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects","volume":"134","author":"Hartung","year":"2014","journal-title":"Pediatrics"},{"key":"10.1124\/dmd.119.086785_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/00498254.2011.625452","article-title":"Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model","volume":"42","author":"Hobbs","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.119.086785_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","article-title":"Liver involvement in early autosomal-dominant polycystic kidney disease","volume":"13","author":"Hogan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/dmd.119.086785_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/aivt.2016.0023","article-title":"Basolateral Efflux Transporters: a potentially important pathway for the prevention of cholestatic hepatotoxicity","volume":"2","author":"Jackson","year":"2016","journal-title":"Appl In Vitro Toxicol"},{"key":"10.1124\/dmd.119.086785_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1538\/expanim.49.51","article-title":"Characterization of a novel polycystic kidney rat model with accompanying polycystic liver","volume":"49","author":"Katsuyama","year":"2000","journal-title":"Exp Anim"},{"key":"10.1124\/dmd.119.086785_bib20","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.510290404","article-title":"Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane","volume":"29","author":"K\u00f6nig","year":"1999","journal-title":"Hepatology"},{"key":"10.1124\/dmd.119.086785_bib21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1523-1755.2001.00473.x","article-title":"The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease","volume":"59","author":"Lager","year":"2001","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.119.086785_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ab.2008.05.032","article-title":"Absolute quantification of multidrug resistance-associated protein 2 (MRP2\/ABCC2) using liquid chromatography tandem mass spectrometry","volume":"380","author":"Li","year":"2008","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.119.086785_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1124\/dmd.108.023234","article-title":"Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2\/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human","volume":"37","author":"Li","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086785_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejps.2019.01.022","article-title":"Protein expression and function of organic anion transporters in short-term and long-term cultures of Huh7 human hepatoma cells","volume":"130","author":"Malinen","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.119.086785_bib25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ar.21166","article-title":"Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD","volume":"293","author":"Mason","year":"2010","journal-title":"Anat Rec (Hoboken)"},{"key":"10.1124\/dmd.119.086785_bib26","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0002-9440(10)63427-X","article-title":"Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease","volume":"165","author":"Masyuk","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1124\/dmd.119.086785_bib27","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1124\/dmd.108.021790","article-title":"Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2)","volume":"36","author":"Miranda","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086785_bib28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2015.05.023","article-title":"Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease","volume":"63","author":"Munoz-Garrido","year":"2015","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.119.086785_bib29","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/dmd.105.007922","article-title":"Altered hepatobiliary disposition of 5 (and 6)-carboxy-2\u2032,7\u2032-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice","volume":"34","author":"Nezasa","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086785_bib30","doi-asserted-by":"crossref","first-page":"G438","DOI":"10.1152\/ajpgi.2000.278.3.G438","article-title":"Characterization of inducible nature of MRP3 in rat liver","volume":"278","author":"Ogawa","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/dmd.119.086785_bib31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1124\/jpet.113.208314","article-title":"Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver","volume":"347","author":"Pfeifer","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.086785_bib32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/dmd.113.053819","article-title":"Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex","volume":"42","author":"Prasad","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086785_bib33","series-title":"Cell Separation: Methods and Selected Applications","first-page":"1","author":"Pretlow","year":"1987"},{"key":"10.1124\/dmd.119.086785_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2003.50006","article-title":"Clinical profile of autosomal dominant polycystic liver disease","volume":"37","author":"Qian","year":"2003","journal-title":"Hepatology"},{"key":"10.1124\/dmd.119.086785_bib35","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1194\/jlr.M040014","article-title":"MALDI imaging MS reveals candidate lipid markers of polycystic kidney disease","volume":"54","author":"Ruh","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1124\/dmd.119.086785_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00003072-198911000-00003","article-title":"Liver cysts associated with polycystic kidney disease: role of Tc-99m hepatobiliary imaging","volume":"14","author":"Salam","year":"1989","journal-title":"Clin Nucl Med"},{"key":"10.1124\/dmd.119.086785_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1198\/000313001317097960","article-title":"On judging the significance of differences by examining overlap between confidence intervals","volume":"55","author":"Schenker","year":"2001","journal-title":"Am Stat"},{"key":"10.1124\/dmd.119.086785_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1091581815611075","article-title":"Age-related alterations in blood biochemical characterization of hepatorenal function in the PCK rat: a model of polycystic kidney disease","volume":"34","author":"Shimomura","year":"2015","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.119.086785_bib39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0091270010376193","article-title":"In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects","volume":"51","author":"Shoaf","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.086785_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfv231","article-title":"Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites: contributing factors to drug-induced liver injury?","volume":"149","author":"Slizgi","year":"2016","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.119.086785_bib41","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.119.086785_bib42","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.119.086785_bib43","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.119.086785_bib44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J Neurochem"},{"key":"10.1124\/dmd.119.086785_bib45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/dmd.114.061580","article-title":"Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics","volume":"43","author":"Wang","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086785_bib46","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","article-title":"Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans","volume":"328","author":"Watanabe","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.086785_bib47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"key":"10.1124\/dmd.119.086785_bib48","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0022-3565(24)38933-5","article-title":"Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR- rats","volume":"295","author":"Xiong","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.086785_bib49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.102.044107","article-title":"Pharmacokinetics of 5 (and 6)-carboxy-2\u2032,7\u2032-dichlorofluorescein and its diacetate promoiety in the liver","volume":"304","author":"Zamek-Gliszczynski","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.086785_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.taap.2016.06.019","article-title":"Dioscin protects against ANIT-induced cholestasis via regulating Oatps, Mrp2 and Bsep expression in rats","volume":"305","author":"Zhang","year":"2016","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.119.086785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:51:33Z","timestamp":1740055893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0090955624080085"],"URL":"https:\/\/doi.org\/10.1124\/dmd.119.086785","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.119.086785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}